Unknown

Dataset Information

0

Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT.


ABSTRACT:

Purpose

Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer.

Methods

Thirty patients with bone metastases originating from prostate cancer were examined by 99mTc-MDP bone scan and 68Ga-PSMA-PET/CT within an average of 21 days. Bone scans were analyzed visually according to the number of lesions and using the software package ExiniBONE by Exini Diagnostics. PET/CT data was analyzed visually. Numbers of detected lesions were compared for the different methods for the whole patient and for different regions. In addition, results were compared to serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), pro gastrin releasing peptide (pGRP) and eastern cooperative oncology group (ECOG) performance status.

Results

In the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases.

Conclusion

No significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied.

SUBMITTER: Thomas L 

PROVIDER: S-EPMC5620612 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between <sup>99m</sup>Tc-Bone-Scintigraphy and [<sup>68</sup>Ga]Ga-PSMA PET/CT.

Thomas Lena L   Balmus Caroline C   Ahmadzadehfar Hojjat H   Essler Markus M   Strunk Holger H   Bundschuh Ralph A RA  

Pharmaceuticals (Basel, Switzerland) 20170731 3


<h4>Purpose</h4>Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer.<h4>Methods</h4>Thirty patients with bone metastases originating from prostate cancer were e  ...[more]

Similar Datasets

| S-EPMC7142208 | biostudies-literature
| S-EPMC7048889 | biostudies-literature
| S-EPMC7072291 | biostudies-literature
| S-EPMC10461474 | biostudies-literature
| S-EPMC7577453 | biostudies-literature
| S-EPMC5355341 | biostudies-literature
| S-EPMC8566391 | biostudies-literature
| S-EPMC9295986 | biostudies-literature
| S-EPMC5944242 | biostudies-literature
| S-EPMC8322807 | biostudies-literature